Ethics and the Pharmaceutical Industry

Santoro, Michael A.; Gorrie, Thomas M.

doi:10.1017/cbo9780511610769

Cited by 21 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ethics is the science of trial and error or the science of good and evil and is a well-established characteristic of the self makes good acts issued by them without cost. When a leader strives for his opinion on any matter, he/she rules his values; ethics and beliefs so that what he/she issues is consistent with what he believes are true (Santoro & Gorrie, 2005).…”

Section: Ethical Leadershipmentioning

confidence: 99%

The role of strategic leadership in increasing ethical practices among pharmaceutical organizations in Jordan

Amayreh¹

2020

10.5267/j.msl

View full text Add to dashboard Cite

This paper aims at examining the influence of strategic leadership on increasing ethical practices within pharmaceutical organizations in Jordan. Variables of strategic leadership include work environment, leader's traits, leadership style and strategic leaders' performance. The study designs a questionnaire and distributes it among (277) employees and leaders within pharmaceutical organizations in Jordan. The results of the study indicate positive influence of strategic leadership on ethical practices among individuals and employees in the organization. Results also indicate that leadership performance maintained the strongest effect on ethical stands attributed from strategic leadership which gives an indication that a good performance strategic leadership is probably more influential on ethical practices and decision making in pharmaceutical organizations. The study recommends that organizations within pharmaceutical industry should pay extra attention to aspects that are related to increase employees' awareness towards ethics in leadership and business.

show abstract

Section: Ethical Leadershipmentioning

confidence: 99%

The role of strategic leadership in increasing ethical practices among pharmaceutical organizations in Jordan

Amayreh¹

2020

10.5267/j.msl

View full text Add to dashboard Cite

show abstract

“…Clinicians should discuss potential life-changing decisions, such as giving up driving, with patient and family in order to avoid potential problems ( 18 ); patients with PD should be treated by a MDT to optimize QOL ( 14 ). However, lack of expertise among health professionals, little interdisciplinary cooperation, and decreased financial support are all barriers to successful MDT care ( 19 ). It is also important to treat patient and carer as a “unit,” with the QOL of the carer linked to the physical and mental health of their charge ( 20 ).…”

Section: Discussion Of the Key Themes From The Interviewsmentioning

confidence: 99%

Challenges to Ethically Managing Parkinson Disease

Shaw¹,

Vivekananda-Schmidt²

2017

Journal of Patient Experience

View full text Add to dashboard Cite

This study investigated the current ethical issues in relation to recognizing and managing Parkinson disease (PD) from the patient’s perspective.Methods:Twelve patients living with PD who were from the medical school’s Patients as Educators program were recruited. Semistructured interviews were conducted to record patient experiences in order to identify potential ethical issues in relation to recognizing and managing PD. Thematic analysis was applied to the interview transcripts.Results:Four key themes emerged from the interviews. These were information giving, coping, identity, and future medical treatment. These data indicate variable experiences in relation to communication between patient and health-care professional, better support for both planning end-of-life decisions and in coping with the disease’s impacts on their identity. Patients with PD also struggle with access to support services and support for main carer.Implications:To ensure ethical practice in supporting patients with PD, these emerging themes need further investigation; and management guidelines relevant to PD must be informed by research in this area to ensure ethical care of patients with PD, their carers, and families.

show abstract

“…The industry is highly profitable thanks largely to revenue from public health schemes and insurance contributions, yet the high costs and risks associated with new drug discovery have been used to justify a growing disengagement from research by the pharmaceutical industry [ 160 ]. If not counterbalanced by broad and dedicated investment in SMEs and universities, this process might be highly detrimental to the already damaged social contract between this industry and society in the short and medium term [ 161 ].…”

Section: Discussionmentioning

confidence: 99%

Current Progress in Structure-Based Rational Drug Design Marks a New Mindset in Drug Discovery

Lounnas

Ritschel

Kelder³

et al. 2013

Computational and Structural Biotechnology Journal

188

123

View full text Add to dashboard Cite

The past decade has witnessed a paradigm shift in preclinical drug discovery with structure-based drug design (SBDD) making a comeback while high-throughput screening (HTS) methods have continued to generate disappointing results. There is a deficit of information between identified hits and the many criteria that must be fulfilled in parallel to convert them into preclinical candidates that have a real chance to become a drug. This gap can be bridged by investigating the interactions between the ligands and their receptors. Accurate calculations of the free energy of binding are still elusive; however progresses were made with respect to how one may deal with the versatile role of water. A corpus of knowledge combining X-ray structures, bioinformatics and molecular modeling techniques now allows drug designers to routinely produce receptor homology models of increasing quality. These models serve as a basis to establish and validate efficient rationales used to tailor and/or screen virtual libraries with enhanced chances of obtaining hits. Many case reports of successful SBDD show how synergy can be gained from the combined use of several techniques. The role of SBDD with respect to two different classes of widely investigated pharmaceutical targets: (a) protein kinases (PK) and (b) G-protein coupled receptors (GPCR) is discussed. Throughout these examples prototypical situations covering the current possibilities and limitations of SBDD are presented.

show abstract

Ethics and the Pharmaceutical Industry

Cited by 21 publications

References 0 publications

The role of strategic leadership in increasing ethical practices among pharmaceutical organizations in Jordan

The role of strategic leadership in increasing ethical practices among pharmaceutical organizations in Jordan

Challenges to Ethically Managing Parkinson Disease

Current Progress in Structure-Based Rational Drug Design Marks a New Mindset in Drug Discovery

Contact Info

Product

Resources

About